Guggenheim lowered the firm’s price target on Sanofi (SNY) to EUR 108 from EUR 121 and keeps a Buy rating on the shares after the company and partner Regeneron (REGN) announced mixed results from itepekimab’s Phase 3 COPD trials. The firm’s price target change is driven by the removal of itepekimab and SAR441566 forecasts, the analyst noted.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SNY:
- Morning Movers: Trump to bump steel tariffs, pharma companies announce deals
- Sanofi acquisition of Blueprint Medicines ‘sensible,’ says BofA
- Sanofi exercises license extension option to Nurix’s STAT6 program
- Sanofi to Acquire Blueprint Medicines for $9.5 Billion, Expanding Rare Disease Portfolio
- Sanofi resumed with an Equal Weight at Morgan Stanley